[{"address1": "7750 El Camino Real", "address2": "Suite 2A", "city": "Carlsbad", "state": "CA", "zip": "92009", "country": "United States", "phone": "858 704 4900", "website": "https://www.palisadebio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.", "fullTimeEmployees": 9, "companyOfficers": [{"maxAge": 1, "name": "Mr. J. D. Finley", "age": 65, "title": "CEO, CFO & Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 791333, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mitchell Lawrence Jones M.D., Ph.D.", "age": 45, "title": "COO & Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 635002, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryker  Willie", "title": "Senior VP of Finance & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 7.29, "open": 7.12, "dayLow": 7.0622, "dayHigh": 7.8899, "regularMarketPreviousClose": 7.29, "regularMarketOpen": 7.12, "regularMarketDayLow": 7.0622, "regularMarketDayHigh": 7.8899, "beta": 1.46, "forwardPE": -0.6531645, "volume": 161784, "regularMarketVolume": 161784, "averageVolume": 1129644, "averageVolume10days": 3719250, "averageDailyVolume10Day": 3719250, "bid": 6.36, "ask": 7.77, "bidSize": 200, "askSize": 200, "marketCap": 6589843, "fiftyTwoWeekLow": 3.82, "fiftyTwoWeekHigh": 36.6, "priceToSalesTrailing12Months": 26.359371, "fiftyDayAverage": 5.737, "twoHundredDayAverage": 9.769, "currency": "USD", "enterpriseValue": -5471156, "floatShares": 836476, "sharesOutstanding": 851401, "sharesShort": 34516, "sharesShortPriorMonth": 3014, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0405, "heldPercentInsiders": 0.01753, "heldPercentInstitutions": 0.1552, "shortRatio": 0.5, "shortPercentOfFloat": 0.0475, "bookValue": 18.301, "priceToBook": 0.42292768, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -12316000, "trailingEps": -27.0, "forwardEps": -11.85, "lastSplitFactor": "1:6", "lastSplitDate": 1619568000, "enterpriseToRevenue": -21.885, "enterpriseToEbitda": 0.426, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "PALI", "underlyingSymbol": "PALI", "shortName": "Palisade Bio, Inc.", "longName": "Palisade Bio, Inc.", "firstTradeDateEpochUtc": 1175261400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "48a6a4f2-9a74-360b-918d-da0f22330672", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.74, "targetHighPrice": 45.0, "targetLowPrice": 22.5, "targetMeanPrice": 33.75, "targetMedianPrice": 33.75, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 12432000, "totalCashPerShare": 14.602, "ebitda": -12841000, "totalDebt": 369000, "quickRatio": 4.865, "currentRatio": 5.154, "totalRevenue": 250000, "debtToEquity": 3.262, "revenuePerShare": 0.548, "returnOnAssets": -0.53853, "returnOnEquity": -1.03396, "freeCashflow": -6471500, "operatingCashflow": -11133000, "grossMargins": 1.0, "operatingMargins": -51.38, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-04"}]